Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients-Reference-Cited by-同舟云学术

Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients

Published:2004-04 Issue:4 Volume:11 Page:253-261
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Almkvist O.,Darreh-Shori T.,Stefanova E.,Spiegel R.,Nordberg A.

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1468-1331.2003.00757.x/fullpdf

Reference52 articles.

1. Functional brain imaging as a looking-glass into the degraded brain: reviewing evidence from Alzheimer disease in relation to normal aging

2. Responder Characteristics to a Single Oral Dose of Cholinesterase Inhibitor: A Double-Blind Placebo-Controlled Study withTacrine in Alzheimer P atients

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuroprotection of Multitargeted Phytochemicals against Alzheimer: A Desperate Need from Nature;The Natural Products Journal;2023-08

2. Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach;Journal of Neuroscience Research;2021-02-26

3. Rivastigmine;Naturally Occurring Chemicals Against Alzheimer's Disease;2021

4. Applications of phytochemicals against nerve agents in counterterrorism;Phytochemistry, the Military and Health;2021

5. Strategies for the use of Ginkgo biloba extract, EGb 761 ® , in the treatment and management of mild cognitive impairment in Asia: Expert consensus;CNS Neuroscience & Therapeutics;2020-12-22